TY - JOUR
T1 - Hepatitis B virus revaccination with standard versus Pre-S vaccine in previously immunized patients with celiac disease
AU - Heshin-Bekenstein, Merav
AU - Turner, Dan
AU - Shamir, Raanan
AU - Bar-Meir, Maskit
AU - Dagan, Ron
AU - Zevit, Noam
AU - Silbermintz, Ari
N1 - Publisher Copyright:
Copyright © 2015 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Objective: Previous studies have suggested that hepatitis B virus (HBV) vaccines may be less immunogenic in individuals with celiac disease (CD). A pre-S vaccine (Sci-B-Vac) has demonstrated superior immunogenicity comparedwith standardHBVvaccines in several diseases.Wecompared the shortterm immunogenicity of a pre-S vaccine with a HBV vaccine (Engerix B) for repeat vaccination of seronegative, previously immunized patients with CD. Methods: Participants were 1 to 18-year-old children with CD who despite standard HBV vaccines in infancy had nonprotective hepatitis B surface antibody (HBs-Ab) concentrations (≤10 mIU/mL). Patients were randomized to receive either Engerix B or pre-S vaccine. HBs-Ab concentrations were measured 1 month after the first dose. For those who had not responded after 1 dose, measurement was repeated after the third dose. Results: Children (n=82) were analyzed (42 pre-S vaccine and 40 Engerix B). Baseline characteristics were similar for both groups, including glutenfree diet status. Both arms showed high response rates following the first injection: 41 (98%) versus 35 (87%) for pre-S vaccine and Engerix B recipients, respectively (P=0.08). All other patients responded when measured after dose 3. HBs-Ab concentrations (mIU/mL) were higher in the pre-S vaccine group (median 925, interquartile range [IQR] 424-1000) than the Engerix B group (median 363, IQR 106-996, P=0.005). Twenty (48%) of the pre-S vaccine recipients were ''high responders'' (>1000 mIU/ mL) versus 10 (25%) in Engerix B recipients (P=0.008). Conclusions: Both vaccines elicited adequate booster responses in most previously vaccinated patients with CD with nonprotective HBs-Ab concentrations. Pre-S vaccine administration resulted in higher Hbs-Ab concentrations. Our data suggest that a single dose of either vaccine is sufficient to raise titers to protective levels in most patients with CD.
AB - Objective: Previous studies have suggested that hepatitis B virus (HBV) vaccines may be less immunogenic in individuals with celiac disease (CD). A pre-S vaccine (Sci-B-Vac) has demonstrated superior immunogenicity comparedwith standardHBVvaccines in several diseases.Wecompared the shortterm immunogenicity of a pre-S vaccine with a HBV vaccine (Engerix B) for repeat vaccination of seronegative, previously immunized patients with CD. Methods: Participants were 1 to 18-year-old children with CD who despite standard HBV vaccines in infancy had nonprotective hepatitis B surface antibody (HBs-Ab) concentrations (≤10 mIU/mL). Patients were randomized to receive either Engerix B or pre-S vaccine. HBs-Ab concentrations were measured 1 month after the first dose. For those who had not responded after 1 dose, measurement was repeated after the third dose. Results: Children (n=82) were analyzed (42 pre-S vaccine and 40 Engerix B). Baseline characteristics were similar for both groups, including glutenfree diet status. Both arms showed high response rates following the first injection: 41 (98%) versus 35 (87%) for pre-S vaccine and Engerix B recipients, respectively (P=0.08). All other patients responded when measured after dose 3. HBs-Ab concentrations (mIU/mL) were higher in the pre-S vaccine group (median 925, interquartile range [IQR] 424-1000) than the Engerix B group (median 363, IQR 106-996, P=0.005). Twenty (48%) of the pre-S vaccine recipients were ''high responders'' (>1000 mIU/ mL) versus 10 (25%) in Engerix B recipients (P=0.008). Conclusions: Both vaccines elicited adequate booster responses in most previously vaccinated patients with CD with nonprotective HBs-Ab concentrations. Pre-S vaccine administration resulted in higher Hbs-Ab concentrations. Our data suggest that a single dose of either vaccine is sufficient to raise titers to protective levels in most patients with CD.
KW - Celiac disease
KW - Hepatitis B vaccine
KW - Pre-S vaccine
KW - Randomized control trial
UR - http://www.scopus.com/inward/record.url?scp=84942516270&partnerID=8YFLogxK
U2 - 10.1097/MPG.0000000000000856
DO - 10.1097/MPG.0000000000000856
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25988560
AN - SCOPUS:84942516270
SN - 0277-2116
VL - 61
SP - 400
EP - 403
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
IS - 4
ER -